All News
ICYMI: Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read Article
ICYMI: Urinary biomarkers precede loss of kidney function for lupus nephritis
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
Read Article
ICYMI: Glucocorticoids-free zone in SLE?
For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.
Read Article
Early bird pricing has been extended! Register today!
https://t.co/BysC0RunUh https://t.co/4Ar0kHa4tt
Links:
Dr. John Cush RheumNow ( View Tweet)
Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now a report of 21 PPP pts given bimekizumab and 17 patients showed complete clearance in 1 to 4 months. SAPHO pts had complete clearance of skin & improved joint pain https://t.co/tYpHCxFOBI https://t.co/i4o3KnGlPY
Dr. John Cush RheumNow ( View Tweet)
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/fOX6VGJQLk https://t.co/u1p1sidCte
Dr. John Cush RheumNow ( View Tweet)
Post-Menopausal Osteoporosis Review and Recommendations
A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations.
https://t.co/TkJjsX98Ww https://t.co/2Hi72GjEHM
Dr. John Cush RheumNow ( View Tweet)
ICYMI: The Heart of Lupus
Few people are aware of the EULAR recommendations1 for cardiovascular (CV) risk management in systemic lupus erythematosus (SLE) published in 2022. The recommendations had 4 overarching principles...
https://t.co/5I5eYNqHIu https://t.co/W6VzUFs6kN
Dr. John Cush RheumNow ( View Tweet)
Withdraw DMARDS after remission?
Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer.
https://t.co/wqcCff7kjx https://t.co/vq9ee1dZNX
Dr. John Cush RheumNow ( View Tweet)
Calcineurin Inhibitors in Lupus Nephritis
Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/1sjvCUyvD9 https://t.co/kocmtM1j6o
Dr. John Cush RheumNow ( View Tweet)
Pneumocystis Jiroveci Pneumonia (PJP) Risk
https://t.co/OTG9Ud1adu https://t.co/jIhdwws0Un
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?
https://t.co/afg5YL3RCN https://t.co/VRyKh6VgmS
Dr. John Cush RheumNow ( View Tweet)
Even low-dose, short-term steroid use increases the risk of serious CV events
Dr. Meral El Ramahi (Nashville, TN) reports on abstract 2430 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/apgxXeVw1U https://t.co/zPiUCqtJlf
Dr. John Cush RheumNow ( View Tweet)
ILD Guidelines Indicators to Screen
Dr. Mike Putman reports from the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/PDE3eZ0Men https://t.co/7xlwrspq9U
Dr. John Cush RheumNow ( View Tweet)
ICYMI: How early is early in PsA?
Guidelines for the management of PsA recommend the early referral of patients with the suspected condition for early assessment and treatment.
https://t.co/9d6WONarwL https://t.co/lNNKzblkEP
Dr. John Cush RheumNow ( View Tweet)
Arthritis & Rheumatology has published a new study that suggests knee or hip osteoarthritis patients who are overweight or obese may have less premature death if slow to moderate rate of weight loss results from anti-obesity medications.
https://t.co/eSwcybRmX5 https://t.co/xEzMwIvAsK
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Who gives a ‘JAK’ why and how they work, as long as they do!
https://t.co/dXp0bDlnMW https://t.co/k0Jl7EX6zt
Dr. John Cush RheumNow ( View Tweet)
Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/30S4si0Luy https://t.co/xlEVEJMoSp
Dr. John Cush RheumNow ( View Tweet)
Cardiac Troponin T and MACE Events in RA
Dr. Arthur Kavanaugh discusses abstract 0387 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/6ZcIQzsv4n https://t.co/34fFk3HTWy
Dr. John Cush RheumNow ( View Tweet)
According to AAMC, clinical neurophysiology has lowest (0.8) number of MDs/100K, while pediatrics has the highest (59.5). In a list of 52, Rheumatology is #17 at mean of 2 Rheums per 100,000 population https://t.co/BrrfSIeHb9 https://t.co/69kRSlk9Dq
Dr. John Cush RheumNow ( View Tweet)